Supplement

You have full text access to this OnlineOpen article

Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors†‡

  1. Appathurai Balamurugan MD, MPH1,§,*,
  2. Faruque Ahmed MD, PhD2,
  3. Mona Saraiya MD, MPH3,
  4. Carol Kosary PhD4,
  5. Molly Schwenn MD5,
  6. Vilma Cokkinides PhD6,
  7. Lisa Flowers MD7,
  8. Lori A. Pollack MD, MPH3

Article first published online: 3 NOV 2008

DOI: 10.1002/cncr.23746

Issue

Cancer

Cancer

Supplement: Assessing the Burden of HPV-Associated Cancers in the United States

Volume 113, Issue Supplement 10, pages 2919–2925, 15 November 2008

Additional Information

How to Cite

Balamurugan, A., Ahmed, F., Saraiya, M., Kosary, C., Schwenn, M., Cokkinides, V., Flowers, L. and Pollack, L. A. (2008), Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors. Cancer, 113: 2919–2925. doi: 10.1002/cncr.23746

Author Information

  1. 1

    Arkansas Central Cancer Registry/Epidemiology Branch, Arkansas Department of Health, Little Rock, Arkansas

  2. 2

    Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, Georgia

  3. 3

    Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, Atlanta, Georgia

  4. 4

    Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland

  5. 5

    Maine Cancer Registry, Maine Center for Disease Control and Prevention, Department of Health and Human Services, Augusta, Maine

  6. 6

    Department of Epidemiology and Research Surveillance, American Cancer Society, Atlanta, Georgia

  7. 7

    Department of Obstetrics and Gynecology, Emory University, Atlanta, Georgia

  1. §

    Fax: (501) 280-4090.

*Epidemiology Branch, Center for Public Health Practice, 4815, W. Markham, Slot H-32, Little Rock, AR 72205

  1. †

    This article is a US Government work and, as such, is in the public domain in the United States of America.

  2. ‡

    The findings and conclusions in this report are those of the authors and do not necessarily reflect the views of the Centers for Disease Control and Prevention.

Publication History

  1. Issue published online: 3 NOV 2008
  2. Article first published online: 3 NOV 2008
  3. Manuscript Accepted: 16 MAY 2008
  4. Manuscript Received: 14 APR 2008

Funded by

  • Cooperative Agreement. Grant Number: U50 DP424071-04
  • Centers for Disease Control and Prevention (CDC)

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (149K)

REFERENCES

  • 1
    Ries LAG,Melbert D,Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. Bethesda, MD: National Cancer Institute; Year. Available at URL: http://seer.cancer.gov/csr/1975_2004/ based on November 2006 SEER data submission, posted to the SEER website, 2007. Published in 2007.
  • 2
    Munoz N,Castellague X,de Gonzalez AB,Gizzmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine. 2006; 24( suppl 3): s1–s10.
  • 3
    Parkin DM,Bray F. The burden of HPV-related cancers. Vaccine. 2006; 24( suppl 3): S3-11–S3/25.
  • 4
    Stuver S,Adami H. Cervical cancer. In: Textbook of Cancer Epidemiology. Oxford: Oxford University Press; 2002.
  • 5
    Mould RF,Barrett A. New primary cancers in patients originally presenting with carcinoma of the cervix. Br J Obstet Gynaecol. 1976; 83: 81–85.
  • 6
    Clarke EA,Kreiger N,Spengler RF. Second primary cancer following treatment for cervical cancer. CMAJ. 1984; 131: 553–556.
  • 7
    Kleinerman RA,Boice JDJr,Storm HH, et al. Second primary cancer after treatment for cervical cancer. An international cancer registries study. Cancer. 1995; 76: 442–452.
    Direct Link:
  • 8
    Fisher G,Harlow SD,Schottenfeld D. Cumulative risk of second primary cancer in women with index primary cancers of uterine cervix and incidence of lower anogenital tract cancers, Michigan, 1985-1992. Gynecol Oncol. 1997; 64: 213–223.
  • 9
    Kleinerman RA,Kosary C,Hildesheim A. New malignancies following cancer of the cervix uteri, vagina, and vulva. In: New malignancies among cancer survivors: SEER Cancer Registries, 1973-2000. NIH Pub. No. 05-5302. Bethesda, MD: National Cancer Institute; 2006: 207–229.
  • 10
    Chaturvedi AK,Engels EA,Gilbert ES, et al. Second cancers among 104760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst. 2007; 99: 1634–1643.
  • 11
    Rambout L,Hopkins L,Hutton B,Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ. 2007; 177: 469–479.
  • 12
    Dillner J,Arbyn M,Dillner L. Translational mini-series on vaccines: monitoring of human papillomavirus vaccination. Clin Exp Immunol. 2007; 148: 199–207.
    Direct Link:
  • 13
    Kahn JA,Lan D,Kahn RS. Sociodemographic factors associated with high-risk human papillomavirus infection. Obstet Gynecol. 2007; 110: 87–95.
  • 14
    JohnsonCH, ed. SEER Program Coding and Staging Manual 2004. Revision 1. NIH Pub. No. 04-5581. Bethesda, MD: National Cancer Institute; 2004.
  • 15
    Watson M, Saraiya M, Ahmed F, et al. Using population-based registry data to assess the burden of HPV-associated cancers in the United States: overview of methods. Cancer. 2008; 113(10 suppl ): 2841–2854.
    Direct Link:
  • 16
    National Cancer Institute. SEER Incidence Site Recode. Bethesda, MD: National Cancer Institute; Year. Available at:http://seer.cancer.gov/siterecode/icdo3_d01272003/. Accessed January 24, 2008. Published in 2008.
  • 17
    Ahmed F,Goodman MT,Kosary C, et al. Excess risk of subsequent primary cancers among colorectal carcinoma survivors, 1975-2001. Cancer. 2006; 107(5 suppl): 1162–1171.
    Direct Link:
  • 18
    National Cancer Institute. Surveillance Research Program SEER*STAT software [computer program]. Version 6.1.4. Bethesda, MD: National Cancer Institute; 2005. Available at: www.seer.cancer.gov/seerstat. Accessed on January 24, 2008.
  • 19
    Boice JDJr. Ionizing radiation. In: SchottenfeldD,FraumeniJFJr, eds.Cancer Epidemiology and Prevention.3rd ed. New York: Oxford University Press; 2006: 259–293.
  • 20
    Thompson B,Coronado G,Neuhouser M,Chen L. Colorectal carcinoma screening among Hispanics and non-Hispanic whites in a rural setting. Cancer. 2005; 103: 2491–2498.
    Direct Link:
  • 21
    Winkleby MA,Snider J,Davis B,Jennings MG,Ahn DK. Cancer-related health behaviors and screening practices among Latinos: findings from a community and agricultural labor camp survey. Ethn Dis. 2003; 13: 376–386.
  • 22
    Castellsague X,Munoz N. Chapter 3: cofactors in human papillomavirus carcinogenesis—role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr. 2003;( 31): 20–28.
  • 23
    Plummer M,Herrero R,Franceschi S, et al. Smoking and cervical cancer: pooled analysis of the IARC multicentric case-control study. Cancer Causes Control. 2003; 14: 805–814.
  • 24
    Demark-Wahnefried W,Aziz NM,Rowland JH,Pinto BM. Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer. J Clin Oncol. 2005; 23: 5814–5830.
  • 25
    Gritz ER,Fingeret MC,Vidrine DJ,Lazev AB,Mehta NV,Reece GP. Successes and failures of the teachable moment: smoking cessation in cancer patients. Cancer. 2006; 106: 17–27.
    Direct Link:
View Full Article (HTML) Get PDF (149K)